LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial

BACKGROUND: Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohlmann, Carsten-Henning, Jäschke, Michelle, Jaehnig, Peter, Krege, Susanne, Gschwend, Jürgen, Rexer, Heidrun, Junker, Kerstin, Zillmann, Roger, Rüssel, Christoph, Hellmis, Eva, Suttmann, Henrik, Janssen, Martin, Marin, Jan, Hübner, Andreas, Mathers, Michael, Gleißner, Jochen, Scheffler, Michael, Feyerabend, Susan, Telle, Jens, Klier, Jörg, Stöckle, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705242/
https://www.ncbi.nlm.nih.gov/pubmed/35430584
http://dx.doi.org/10.1038/s41391-022-00533-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705242/
https://www.ncbi.nlm.nih.gov/pubmed/35430584
http://dx.doi.org/10.1038/s41391-022-00533-6

Ejemplares similares